Answer
Elrexfio (elranatamab) is indicated as monotherapy for adults with relapsed and refractory multiple myeloma who received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose disease progressed on the last therapy.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 8Document updated
Sources checked